Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

This study is looking at what happens in the body when people with mouth cancer (oral cavity cancer) receive an immunotherapy drug before surgery. Researchers want to find biological markers that predict who responds well to this treatment. **You may be eligible if...** - You are 18 or older and have been diagnosed with stage II–IVB oral cavity cancer (tongue, floor of mouth, cheek, gum, lip, or hard palate) - Your tumor is at least 2 cm and can be surgically removed - You have not yet received chemotherapy or immunotherapy for this cancer - You are in generally good health (able to do basic daily activities) **You may NOT be eligible if...** - You have an autoimmune disease requiring immune-suppressing medications (some exceptions apply) - You are pregnant or breastfeeding - You have another active cancer being treated (some exceptions apply) - You have previously received immunotherapy (PD-1/PD-L1 drugs) - You have had a live vaccine in the last 30 days - You have had a history of lung inflammation requiring steroids, or had an organ transplant Talk to your doctor to see if this trial is right for you.